MX2023010882A - Compuestos y composiciones para el tratamiento de trastornos hematológicos. - Google Patents
Compuestos y composiciones para el tratamiento de trastornos hematológicos.Info
- Publication number
- MX2023010882A MX2023010882A MX2023010882A MX2023010882A MX2023010882A MX 2023010882 A MX2023010882 A MX 2023010882A MX 2023010882 A MX2023010882 A MX 2023010882A MX 2023010882 A MX2023010882 A MX 2023010882A MX 2023010882 A MX2023010882 A MX 2023010882A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- hematological disorders
- compositions
- treating hematological
- treating
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000014951 hematologic disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 abstract 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 abstract 1
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 abstract 1
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona métodos para tratar trastornos hematológicos y tumores malignos sólidos usando compuestos de indazol sustituidos y sales farmacéuticamente aceptables de estos. Los compuestos inhiben las cinasas IRAK4 y BCL-2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762579502P | 2017-10-31 | 2017-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023010882A true MX2023010882A (es) | 2023-09-27 |
Family
ID=66328095
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020003666A MX2020003666A (es) | 2017-10-31 | 2018-10-30 | Compuestos y composiciones para el tratamiento de trastornos hematologicos. |
MX2023010882A MX2023010882A (es) | 2017-10-31 | 2020-07-13 | Compuestos y composiciones para el tratamiento de trastornos hematológicos. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020003666A MX2020003666A (es) | 2017-10-31 | 2018-10-30 | Compuestos y composiciones para el tratamiento de trastornos hematologicos. |
Country Status (15)
Country | Link |
---|---|
US (3) | US10758518B2 (es) |
EP (1) | EP3704108B1 (es) |
JP (2) | JP7241747B2 (es) |
KR (1) | KR20200080254A (es) |
CN (2) | CN111225911B (es) |
AU (2) | AU2018359248B2 (es) |
BR (1) | BR112020008214A2 (es) |
CA (1) | CA3079628A1 (es) |
EA (1) | EA202090497A1 (es) |
FI (1) | FI3704108T3 (es) |
IL (2) | IL308364A (es) |
MX (2) | MX2020003666A (es) |
PH (1) | PH12020550457A1 (es) |
SG (1) | SG11202002386WA (es) |
WO (1) | WO2019089580A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3094329T3 (en) | 2014-01-13 | 2018-11-19 | Aurigene Discovery Tech Ltd | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAC4 INHIBITORS |
MX2019011158A (es) | 2017-03-31 | 2019-10-17 | Aurigene Discovery Tech Ltd | Compuestos y composiciones para tratar trastornos hematologicos. |
MX2022003504A (es) * | 2019-09-24 | 2022-07-19 | Shanghai Meiyue Biotech Dev Co Ltd | Inhibidor de irak y metodo de preparacion para el mismo y uso del mismo. |
WO2021204589A1 (en) | 2020-04-07 | 2021-10-14 | Bayer Aktiengesellschaft | Substituted thiazolopyridines, salts thereof and their use as herbicidally active substances |
CN116419752A (zh) * | 2020-08-03 | 2023-07-11 | 柯瑞斯公司 | 用于治疗疾病和病症的组合物和方法 |
CN116710776A (zh) * | 2020-11-18 | 2023-09-05 | 柯里斯公司 | 治疗疾病和病症的方法 |
CN116745294A (zh) * | 2020-12-25 | 2023-09-12 | 南京明德新药研发有限公司 | 酰胺噁唑类化合物 |
IL307465A (en) * | 2021-04-08 | 2023-12-01 | Curis Inc | Combined therapies for cancer treatment |
CN113402499B (zh) | 2021-06-21 | 2022-05-13 | 上海勋和医药科技有限公司 | 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途 |
TW202328151A (zh) | 2021-09-07 | 2023-07-16 | 德商拜耳廠股份有限公司 | 經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途 |
TW202328150A (zh) | 2021-09-07 | 2023-07-16 | 德商拜耳廠股份有限公司 | 經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途 |
CN117177965B (zh) * | 2021-12-23 | 2024-04-30 | 杭州多域生物技术有限公司 | 一种五元并六元化合物、制备方法、药物组合物和应用 |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
US5494911A (en) | 1990-05-18 | 1996-02-27 | Hoechst Aktiengesellschaft | Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use |
GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
CA2296080C (en) | 1997-07-29 | 2005-02-01 | Alcon Laboratories, Inc. | Ophthalmic compositions containing galactomannan polymers and borate |
US6110973A (en) | 1998-01-29 | 2000-08-29 | Sepracor | Methods for treating obesity and weight gain using optically pure (-)-bupropion |
US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
DE10023486C1 (de) | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
RS20050789A (sr) | 2003-05-01 | 2008-04-04 | Bristol-Myers Squibb Company, | Aril-supstituisana jedinjenja pirazol-amida pogodna za primenu kao inhibitori kinaze |
EP2281823A3 (en) | 2003-05-20 | 2011-09-07 | Ajinomoto Co., Inc. | Anti-inflammatory and analgesic piperidine derivatives |
US20050004133A1 (en) | 2003-06-05 | 2005-01-06 | Makings Lewis R. | Modulators of VR1 receptor |
US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
WO2005034870A2 (en) | 2003-10-07 | 2005-04-21 | Renovis, Inc. | Amide compounds and ion channel ligands and uses thereof |
CA2563941C (en) | 2004-04-22 | 2014-10-07 | Bayer Cropscience Lp | Method and composition for controlling weeds with a combination of a preemergent, a post emergent and a three-way broadleaf herbicidal compositions |
US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
EP1655297A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
WO2006053227A2 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Il-12 modulatory compounds |
WO2006066174A1 (en) | 2004-12-17 | 2006-06-22 | Eli Lilly And Company | Thiazolopyridinone derivates as mch receptor antagonists |
EP1828177B1 (en) | 2004-12-17 | 2008-08-13 | Eli Lilly And Company | Novel mch receptor antagonists |
EP1674467A1 (en) | 2004-12-22 | 2006-06-28 | 4Sc Ag | 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors |
WO2007058626A1 (en) | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
CN102633783A (zh) | 2006-02-10 | 2012-08-15 | 转化技术制药公司 | 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法 |
GB0606429D0 (en) | 2006-03-30 | 2006-05-10 | Novartis Ag | Organic compounds |
US8008481B2 (en) | 2006-03-31 | 2011-08-30 | Ericsson Anna M | Indazole compounds |
US20080293785A1 (en) | 2006-04-11 | 2008-11-27 | Connolly Peter J | Substituted benzothiazole kinase inhibitors |
CN101594909A (zh) | 2006-09-07 | 2009-12-02 | 比奥根艾迪克Ma公司 | 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂 |
CA2663100A1 (en) | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase |
US20080153810A1 (en) | 2006-11-15 | 2008-06-26 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
EP2121621B1 (en) | 2006-12-08 | 2014-05-07 | Exelixis Patent Company LLC | Lxr and fxr modulators |
JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
WO2009012312A1 (en) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases |
US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
US8399448B2 (en) | 2007-08-08 | 2013-03-19 | Merck Serono Sa | 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis |
EP2252617A1 (en) | 2008-02-13 | 2010-11-24 | CGI Pharmaceuticals, Inc. | 6-aryl-imidaz0[l, 2-a]pyrazine derivatives, method of making, and method of use thereof |
AU2009316786A1 (en) | 2008-11-19 | 2010-05-27 | Merck Sharp & Dohme Corp. | Inhibitors of diacylglycerol acyltransferase |
EP2379564A1 (en) | 2008-12-19 | 2011-10-26 | Schering Corporation | Bicyclic heterocyclic derivatives and methods of use thereof |
CA2745866A1 (en) | 2008-12-23 | 2010-07-01 | F.Hoffmann-La Roche Ag | Dihydropyridone ureas as p2x7 modulators |
CA2777565C (en) | 2009-10-13 | 2019-06-18 | Ligand Pharmaceuticals Inc. | Hematopoietic growth factor mimetic diphenylamine small molecule compounds and their uses |
ES2545811T3 (es) | 2010-04-22 | 2015-09-16 | Janssen Pharmaceutica Nv | Compuestos de indazol útiles como inhibidores de quetohexoquinasa |
AU2011245299A1 (en) | 2010-04-30 | 2012-08-30 | Merck Sharp & Dohme Corp. | Inhibitors of phosphoinositide dependent kinase 1 (PDK1) |
DK2585064T3 (en) | 2010-06-24 | 2017-07-24 | Chemocentryx Inc | C5aR antagonists |
RU2604062C2 (ru) | 2010-07-13 | 2016-12-10 | Ф.Хоффманн-Ля Рош Аг | ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА И ТИЕНО[3,2-b]ПИРИМИДИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ IRAK-4 |
EP2730564B1 (en) | 2010-11-19 | 2018-04-18 | Ligand Pharmaceuticals Inc. | Heterocycle amines and uses thereof |
US9073892B2 (en) | 2010-12-20 | 2015-07-07 | Merck Serono S.A. | Indazolyl triazol derivatives |
EP2696873B1 (en) | 2011-04-12 | 2022-08-03 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria |
WO2013042137A1 (en) | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Bicyclic heterocycles as irak4 inhibitors |
JP6073343B2 (ja) | 2011-10-20 | 2017-02-01 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ |
GB201119401D0 (en) | 2011-11-10 | 2011-12-21 | Ucb Pharma Sa | Therapeutic agents |
KR101385603B1 (ko) | 2012-05-17 | 2014-04-21 | 한국원자력의학원 | 벤조티아졸 유도체 및 암 치료를 위한 그의 용도 |
WO2014003483A1 (en) | 2012-06-29 | 2014-01-03 | Hanmi Pharm. Co., Ltd. | Fused pyrimidine derivatives having inhibitory activity on fms kinases |
WO2014011902A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
US9334249B2 (en) | 2012-11-03 | 2016-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of cytomegalovirus |
CA2907960C (en) | 2013-05-22 | 2021-10-19 | Children's Hospital Medical Center | Combination therapy for mds |
TWI652014B (zh) | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
SG11201605408RA (en) | 2014-01-10 | 2016-07-28 | Aurigene Discovery Tech Ltd | Indazole compounds as irak4 inhibitors |
DK3094329T3 (en) * | 2014-01-13 | 2018-11-19 | Aurigene Discovery Tech Ltd | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAC4 INHIBITORS |
SG11201606367YA (en) | 2014-02-06 | 2016-09-29 | Abbvie Inc | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof |
BR112016029853A2 (pt) | 2014-06-20 | 2017-08-22 | Aurigene Discovery Tech Ltd | compostos de indazol substituído como inibidores de irak4 |
AU2016293446A1 (en) | 2015-07-15 | 2018-02-15 | Aurigene Discovery Technologies Limited | Substituted aza compounds as IRAK-4 inhibitors |
BR112018000624A2 (pt) | 2015-07-15 | 2018-09-18 | Aurigene Discovery Technologies Limited | compostos de indazol e azaindazol como inibidores de irak-4 |
DK3331879T3 (da) * | 2015-08-04 | 2020-08-10 | Rigel Pharmaceuticals Inc | Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne |
EP3532164A4 (en) | 2016-10-28 | 2020-10-07 | Children's Hospital Medical Center | TREATMENT OF DISEASES RELATED TO ACTIVATED IRAQ |
-
2018
- 2018-10-30 FI FIEP18873778.7T patent/FI3704108T3/fi active
- 2018-10-30 IL IL308364A patent/IL308364A/en unknown
- 2018-10-30 AU AU2018359248A patent/AU2018359248B2/en active Active
- 2018-10-30 CN CN201880066904.0A patent/CN111225911B/zh active Active
- 2018-10-30 WO PCT/US2018/058194 patent/WO2019089580A1/en unknown
- 2018-10-30 CA CA3079628A patent/CA3079628A1/en active Pending
- 2018-10-30 JP JP2020523028A patent/JP7241747B2/ja active Active
- 2018-10-30 EA EA202090497A patent/EA202090497A1/ru unknown
- 2018-10-30 IL IL274248A patent/IL274248B1/en unknown
- 2018-10-30 SG SG11202002386WA patent/SG11202002386WA/en unknown
- 2018-10-30 CN CN202311020285.0A patent/CN117064897A/zh active Pending
- 2018-10-30 KR KR1020207013352A patent/KR20200080254A/ko active IP Right Grant
- 2018-10-30 EP EP18873778.7A patent/EP3704108B1/en active Active
- 2018-10-30 MX MX2020003666A patent/MX2020003666A/es unknown
- 2018-10-30 BR BR112020008214-7A patent/BR112020008214A2/pt unknown
- 2018-10-31 US US16/176,940 patent/US10758518B2/en active Active
-
2020
- 2020-04-21 PH PH12020550457A patent/PH12020550457A1/en unknown
- 2020-07-13 MX MX2023010882A patent/MX2023010882A/es unknown
- 2020-07-21 US US16/934,724 patent/US20200345704A1/en not_active Abandoned
-
2021
- 2021-12-30 US US17/566,371 patent/US20220370422A1/en active Pending
-
2023
- 2023-03-07 JP JP2023034551A patent/JP7476380B2/ja active Active
- 2023-08-30 AU AU2023222890A patent/AU2023222890A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2018359248B2 (en) | 2023-06-01 |
EP3704108B1 (en) | 2024-04-24 |
US20220370422A1 (en) | 2022-11-24 |
BR112020008214A2 (pt) | 2020-10-27 |
AU2018359248A1 (en) | 2020-03-26 |
US10758518B2 (en) | 2020-09-01 |
CN117064897A (zh) | 2023-11-17 |
CN111225911B (zh) | 2023-09-01 |
PH12020550457A1 (en) | 2021-03-22 |
EP3704108A1 (en) | 2020-09-09 |
IL274248A (en) | 2020-06-30 |
IL308364A (en) | 2024-01-01 |
WO2019089580A1 (en) | 2019-05-09 |
SG11202002386WA (en) | 2020-04-29 |
JP7476380B2 (ja) | 2024-04-30 |
KR20200080254A (ko) | 2020-07-06 |
IL274248B1 (en) | 2024-02-01 |
FI3704108T3 (fi) | 2024-05-23 |
JP2023071915A (ja) | 2023-05-23 |
JP7241747B2 (ja) | 2023-03-17 |
MX2020003666A (es) | 2020-08-03 |
JP2021501145A (ja) | 2021-01-14 |
CN111225911A (zh) | 2020-06-02 |
US20200345704A1 (en) | 2020-11-05 |
EA202090497A1 (ru) | 2020-11-23 |
EP3704108A4 (en) | 2021-08-25 |
US20190134010A1 (en) | 2019-05-09 |
CA3079628A1 (en) | 2019-05-09 |
AU2023222890A1 (en) | 2023-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023010882A (es) | Compuestos y composiciones para el tratamiento de trastornos hematológicos. | |
PH12019502138A1 (en) | Compounds and compositions for treating hematological disorders | |
MX2023004593A (es) | Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos. | |
MX2020011747A (es) | Terapias genicas para los trastornos lisosomales. | |
MX2022002877A (es) | Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos. | |
PH12018502102A1 (en) | Pyrrolotriazine compounds as tam inhibitors | |
PH12017502203A1 (en) | Tyrosine kinase inhibitors | |
MX2019012038A (es) | Composiciones que comprenden una combinacion de un anticuerpo anti gen 3 de activacion del linfocito (lag-3), un inhibidor de la trayectoria del receptor de muerte programada 1 (pd-1), y un agente inmunoterapeutico. | |
MX2023008031A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
EP3848370A3 (en) | Tyk2 inhibitors and uses thereof | |
WO2018140831A3 (en) | Tumor targeting conjugates and methods of use thereof | |
PH12018501268A1 (en) | Compounds useful as kinase inhibitors | |
MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
MX2022005780A (es) | Moduladores de receptores estrogenicos. | |
PH12018502535A1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
MX2020011745A (es) | Terapias genicas para los trastornos lisosomales. | |
EP4327809A3 (en) | Tyk2 inhibitors and uses thereof | |
PH12020551853A1 (en) | Axl kinase inhibitors and use of the same | |
WO2018237379A3 (en) | COMPOUNDS MODULATING THE PATH OF SPHINGOSINE FOR THE TREATMENT OF CANCERS | |
WO2017123568A3 (en) | Methods for the treatment of myeloid derived suppressor cells related disorders | |
MX2020011826A (es) | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. | |
MX2019007041A (es) | Metodos y composiciones para tratar la enfermedad de parkinson. | |
IL291351A (en) | Pharmaceutical preparations for the treatment of solid tumors | |
MX2021011699A (es) | Derivados de quinolina y su uso para el tratamiento del cancer. | |
EA201792676A1 (ru) | Ингибиторы jak1 |